UBS AM
ZYME icon

UBS AM’s Zymeworks ZYME Stock Holding History

UBS AM’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13M Sell
81,359
-238,026
-75% -$6.05M ﹤0.01% 2023
2026
Q1 		$8M Sell
319,385
-876
-0.3% -$20.7K ﹤0.01% 1326
2025
Q4 		$8.43M Sell
320,261
-1,390,202
-81% -$30.3M ﹤0.01% 1198
2025
Q3 		$29.2M Sell
1,710,463
-749,050
-30% -$10.7M 0.01% 720
2025
Q2 		$30.9M Sell
2,459,513
-1,420,432
-37% -$16.9M 0.01% 879
2025
Q1 		$46.2M Buy
3,879,945
+2,514,834
+184% +$34.3M 0.01% 701
2024
Q4 		$20M Sell
1,365,111
-158,973
-10% -$2.22M ﹤0.01% 954
2024
Q3 		$19.1M Sell
1,524,084
-378,317
-20% -$4.12M ﹤0.01% 964
2024
Q2 		$16.2M Buy
1,902,401
+1,846,100
+3,279% +$16.4M ﹤0.01% 946
2024
Q1 		$592K Hold
56,301
– – ﹤0.01% 2231
2023
Q4 		$585K Hold
56,301
– – ﹤0.01% 2268
2023
Q3 		$357K Buy
56,301
+12,901
+30% +$95.3K ﹤0.01% 2392
2023
Q2 		$392K Hold
43,400
– – ﹤0.01% 2396
2023
Q1 		$392K Buy
+43,400
New +$378K ﹤0.01% 2396
2022
Q2 		– Sell
-336,008
Closed -$2.2M – 2781
2022
Q1 		$2.2M Sell
336,008
-74,207
-18% -$661K ﹤0.01% 1752
2021
Q4 		$6.72M Sell
410,215
-257,774
-39% -$5.37M ﹤0.01% 1278
2021
Q3 		$19.4M Sell
667,989
-116,355
-15% -$3.87M 0.01% 878
2021
Q2 		$27.2M Sell
784,344
-245,368
-24% -$7.78M 0.01% 805
2021
Q1 		$32.5M Buy
1,029,712
+384,752
+60% +$15.6M 0.01% 728
2020
Q4 		$30.5M Buy
644,960
+3,587
+0.6% +$167K 0.01% 738
2020
Q3 		$29.9M Buy
641,373
+232,255
+57% +$7.97M 0.02% 658
2020
Q2 		$14.8M Buy
409,118
+267,619
+189% +$9.86M 0.01% 822
2020
Q1 		$5.02M Sell
141,499
-22,620
-14% -$926K ﹤0.01% 1047
2019
Q4 		$7.46M Buy
+164,119
New +$5.96M ﹤0.01% 1052

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

UBS AM's ZYME Position: Q2 2026 in Review

UBS AM reduced its Zymeworks (ZYME) stake by 75% in Q2 2026, selling an estimated $6.05M and leaving 81,359 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2023.

UBS AM first reported a position in ZYME in Q4 2019 and has held it in 24 quarters since. The position peaked at $46.2M in Q1 2025. 203 funds tracked by Wall St. Rank hold ZYME as of Q2 2026.

  • UBS AM held 81,359 shares of Zymeworks worth $2.13M as of Q2 2026.
  • UBS AM sold 238,026 Zymeworks shares in Q2 2026, an estimated $6.05M.
  • Zymeworks made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2023 holding.
  • UBS AM first reported a position in Zymeworks in Q4 2019 and has held it in 24 quarters since.
  • UBS AM's Zymeworks position peaked at $46.2M in Q1 2025.
  • 203 funds tracked by Wall St. Rank held Zymeworks as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.